Ohr Pharmaceutical Announces Closing of SKS Ocular Acquisition; Strengthens Executive Management Team
June 02, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
Jason Slakter, MD Appointed Chief Medical Officer
Glenn L. Stoller, MD Appointed Chief Scientific Officer
Peter K. Kaiser, MD Appointed as Senior Vice President of Product Development
NEW...
Ohr Pharmaceutical Announces Agreement to Acquire Technology Assets of SKS Ocular
May 15, 2014 16:01 ET
|
Ohr Pharmaceutical, Inc.
Transaction Expands Ohr's Pipeline to Include Multiple New Drug Candidates in Ophthalmology
Provides Ohr with Proprietary Sustained Release Drug Delivery Platform for Ocular Drugs
Upfront...
Long Island Capital Alliance Announces Highly Successful Biotech Capital Forum
May 15, 2014 09:00 ET
|
Long Island Capital Alliance
MELVILLE, NY--(Marketwired - May 15, 2014) - The Long Island Capital Alliance ("LICA"), the leading non-profit capital formation and business development organization serving regional companies,...
Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema
May 09, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II...
Vista Partners Publishes May 2014 Macroeconomic & Investment Newsletter
May 02, 2014 09:00 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - May 2, 2014) - Vista Partners ("Vista") published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from...
Long Island Capital Alliance Announces Participants for Biotech Capital Forum to Be Held on May 9
May 01, 2014 09:00 ET
|
Long Island Capital Alliance
MELVILLE, NY--(Marketwired - May 1, 2014) - The Long Island Capital Alliance ("LICA"), the leading non-profit capital formation and business development organization serving regional companies,...
Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD
April 29, 2014 05:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...
Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock
April 08, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...
Ohr Pharmaceutical to Present at the 26th Annual ROTH Conference
March 10, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced...
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
March 07, 2014 09:00 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Mar 7, 2014) - Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each...